Need help finding what you are looking for?
Contact Us
PUBLISHER: Grand View Research | PRODUCT CODE: 1571744
PUBLISHER: Grand View Research | PRODUCT CODE: 1571744
Europe Bladder Cancer Diagnostics Market Size, Share & Trends Analysis Report By Technology (Cystoscopy, Ultrasound), By Cancer Type (Transitional Cell Bladder, Squamous Cell Bladder), By End-use, By Country, And Segment Forecasts, 2024 - 2030
PUBLISHED:
PAGES: 150 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
Europe Bladder Cancer Diagnostics Market Growth & Trends:
The Europe bladder cancer diagnostics market size is expected to reach USD 1.33 billion by 2030, registering a CAGR of 8.38% from 2024 to 2030, according to a new report by Grand View Research, Inc. The increasing prevalence of bladder cancer, advancements in diagnostic technologies such as liquid biopsy and urine-based tests, and rising awareness about early cancer detection contribute significantly to market growth. Additionally, supportive government initiatives and growing healthcare expenditure further propel the demand for advanced diagnostics. The aging population in Europe, coupled with lifestyle factors such as smoking and exposure to carcinogens, also boosts the need for timely and accurate bladder cancer diagnostics. The market is expected to continue expanding with technological innovations.
Non-muscle Invasive Bladder Cancer (NMIBC) remains a significant global health issue, with nearly half of the diagnosed cases experiencing recurrences or progression to Muscle-invasive Bladder Cancer (MIBC). Factors contributing to this include misdiagnosis, delays in diagnosis, and incomplete tumor resection. Missing early recurrence of high-risk lesions in NMIBC can significantly delay appropriate treatments, negatively impacting disease prognosis.
Accurate and timely diagnosis of NMIBC is critical for proper risk stratification, decision-making, and treatment planning. Precision diagnostics rely on clinical presentation and traditional risk factors and provide deeper insights into the genetic and molecular characteristics of tumors, identifying potential drivers of aggressive behavior. Combining conventional diagnostics such as radiology and cystoscopy with emerging technologies-such as next-generation imaging, immunohistochemical biomarkers, Next-Generation Sequencing (NGS), multi-omics, and AI/machine learning-has the potential to improve diagnostic precision, leading to more effective and cost-efficient care.
In NMIBC, AI is increasingly being studied in clinical trials. One tool recently evaluated in a clinical study uses comprehensive molecular profiling to assess pre- and post-treatment responses to BCG immunotherapy. The aim is to create personalized models for predicting treatment response. Another tool, PROGRxN-BCa, presented at the 2024 AUA Congress, outperformed current methods in predicting disease progression, helping avoid unnecessary treatment escalation. A systematic review of AI in NMIBC also found that AI models outperformed traditional methods in predicting outcomes.
Despite these advancements, challenges remain in implementing precision diagnostics more widely. Limited high-quality clinical data, lack of guideline recommendations, high equipment costs, and regulatory hurdles are significant barriers. Collaboration between healthcare professionals and AI developers is crucial for building better models and advancing NMIBC care to the next level.
In 2024, the World Bladder Cancer Patient Coalition (WBCPC) and the European Association of Urology (EAU) are launching a White Paper on Bladder Cancer. Aimed at EU and national policymakers, this advocacy resource addresses key challenges faced by patients and caregivers, offering recommendations to improve bladder cancer care. The White Paper also seeks to raise awareness among policymakers in light of Europe's Beating Cancer Plan and the upcoming 2024 EU elections. The goal is to inspire policy actions focused on addressing neglected cancers like bladder cancer and closing gaps in cancer care by ensuring access to timely, accurate diagnosis and high-quality treatment.
Europe Bladder Cancer Diagnostics Market Report Highlights:
- Based on technology, cystoscopy accounted for the largest revenue share of 47.54% in 2023. Cystoscopy is a key diagnostic technology in the Europe bladder cancer diagnostics market, enabling direct visualization of the bladder. Its integration with other diagnostic modalities enhances early detection and monitoring, contributing to market growth
- Based on cancer type, transitional cell bladder dominated the market and accounted for the largest share of 87.39% in 2023.Transitional Cell Bladder Cancer (TCBC) holds a significant market share in the European bladder cancer diagnostics market, as it represents over 90% of bladder cancer cases in the region. Its predominance drives the need for advanced diagnostic methods to improve early detection and treatment outcomes. The market's growth reflects a focus on comprehensive diagnostic approaches, including cystoscopy, molecular testing, and imaging, essential for accurate detection & staging of TCBC. The emphasis on these methods is crucial for addressing the high incidence rates and optimizing patient management strategies in Europe
- Based on end use, hospital settings dominated the market with the largest share of 75.51% in 2023. This reflects the significant reliance on hospitals for advanced diagnostic procedures and treatments
- The non-hospital settings segment is expected to experience the fastest growth, driven by an anticipated CAGR of 8.99% over the forecast period. This growth is likely due to the increasing availability of diagnostic technologies in outpatient clinics, private labs, and home-based testing, enabling broader access to diagnostics outside traditional hospital environments and catering to patient demand for more convenient options
- Germany dominated the Europe bladder cancer diagnostics market. The German market is expanding with key advancements. Key player contribution in enhancing patient care and communication, setting the stage for future market growth. The European uCAIR project's funding aims to revolutionize biopsy analysis with rapid, AI-integrated Raman imaging, improving diagnostic speed and accuracy
Product Code: GVR-4-68040-467-2
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Technology
- 1.2.2. Cancer Type
- 1.2.3. End Use
- 1.2.4. Regional scope
- 1.2.5. Estimates and forecasts timeline.
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR's internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.4.5. Details of primary research
- 1.5. Information or Data Analysis
- 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Approach 1: Commodity flow approach
- 1.7.3. Volume price analysis (Model 2)
- 1.7.4. Approach 2: Volume price analysis
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Technology outlook
- 2.2.2. Cancer Type outlook
- 2.2.3. End Use outlook
- 2.2.4. Regional outlook
- 2.3. Competitive Insights
Chapter 3. Europe Bladder Cancer Diagnostics Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook.
- 3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.1.1. Advancements in non-invasive diagnostics
- 3.2.1.2. Shifting to a precision-based approach in NMIBC
- 3.2.1.3. Rising awareness for the early diagnosis of bladder cancer
- 3.2.2. Market restraint analysis
- 3.2.2.1. High cost associated with diagnosis and treatment of bladder cancer
- 3.2.1. Market driver analysis
- 3.3. Europe Bladder Cancer Diagnostics Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
- 3.3.2. PESTEL Analysis
Chapter 4. Europe Bladder Cancer Diagnostics Market: Technology Estimates & Trend Analysis
- 4.1. Segment Dashboard
- 4.2. Europe Bladder Cancer Diagnostics Market: Technology Movement Analysis
- 4.3. Europe Bladder Cancer Diagnostics Market Size & Trend Analysis, by diagnostic technique, 2018 to 2030 (USD Million)
- 4.4. Cystoscopy
- 4.4.1. Cystoscopy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.5. Ultrasound
- 4.5.1. Ultrasound Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.6. Urinalysis
- 4.6.1. Urinalysis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.7. Others
- 4.7.1. Others Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. Europe Bladder Cancer Diagnostics Market: Cancer Type Estimates & Trend Analysis
- 5.1. Cancer Type Market Share, 2023 & 2030
- 5.2. Segment Dashboard
- 5.3. Europe Bladder Cancer Diagnostics Market by Cancer Type Outlook
- 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 5.5. Transitional Cell Bladder Cancer
- 5.5.1. Transitional Cell Bladder Cancer Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.6. Squamous Cell Bladder Cancer
- 5.6.1. Squamous Cell Bladder Cancer Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.7. Others
- 5.7.1. Others Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. Europe Bladder Cancer Diagnostics Market: End Use Estimates & Trend Analysis
- 6.1. End Use Market Share, 2023 & 2030
- 6.2. Segment Dashboard
- 6.3. Europe Bladder Cancer Diagnostics Market by End Use Outlook
- 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 6.5. Hospital Settings
- 6.5.1. Hospital Settings Market estimates and forecasts 2018 to 2030 (USD Million)
- 6.6. Non Hospital Settings
- 6.6.1. Non Hospital Settings Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. Europe Bladder Cancer Diagnostics Market: Regional Estimates & Trend Analysis
- 7.1. Country Market Share Analysis, 2023 & 2030
- 7.2. Country Market Dashboard
- 7.3. Country Market Snapshot
- 7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
- 7.5. Europe
- 7.5.1. UK
- 7.5.1.1. Key country dynamics
- 7.5.1.2. Regulatory framework/Reimbursement
- 7.5.1.3. Competitive scenario
- 7.5.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.2. Germany
- 7.5.2.1. Key country dynamics
- 7.5.2.2. Regulatory framework/Reimbursement
- 7.5.2.3. Competitive scenario
- 7.5.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.3. France
- 7.5.3.1. Key country dynamics
- 7.5.3.2. Regulatory framework/Reimbursement
- 7.5.3.3. Competitive scenario
- 7.5.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.4. Italy
- 7.5.4.1. Key country dynamics
- 7.5.4.2. Regulatory framework/Reimbursement
- 7.5.4.3. Competitive scenario
- 7.5.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.5. Spain
- 7.5.5.1. Key country dynamics
- 7.5.5.2. Regulatory framework/Reimbursement
- 7.5.5.3. Competitive scenario
- 7.5.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.6. Norway
- 7.5.6.1. Key country dynamics
- 7.5.6.2. Regulatory framework/Reimbursement
- 7.5.6.3. Competitive scenario
- 7.5.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.7. Sweden
- 7.5.7.1. Key country dynamics
- 7.5.7.2. Regulatory framework/Reimbursement
- 7.5.7.3. Competitive scenario
- 7.5.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.8. Denmark
- 7.5.8.1. Key country dynamics
- 7.5.8.2. Regulatory framework/Reimbursement
- 7.5.8.3. Competitive scenario
- 7.5.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.9. Poland
- 7.5.9.1. Key country dynamics
- 7.5.9.2. Regulatory framework/Reimbursement
- 7.5.9.3. Competitive scenario
- 7.5.9.4. Poland market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.10. Finland
- 7.5.10.1. Key country dynamics
- 7.5.10.2. Regulatory framework/Reimbursement
- 7.5.10.3. Competitive scenario
- 7.5.10.4. Finland market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.11. Estonia
- 7.5.11.1. Key country dynamics
- 7.5.11.2. Regulatory framework/Reimbursement
- 7.5.11.3. Competitive scenario
- 7.5.11.4. Estonia market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.12. Latvia
- 7.5.12.1. Key country dynamics
- 7.5.12.2. Regulatory framework/Reimbursement
- 7.5.12.3. Competitive scenario
- 7.5.12.4. Latvia market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.13. Latvia
- 7.5.13.1. Key country dynamics
- 7.5.13.2. Regulatory framework/Reimbursement
- 7.5.13.3. Competitive scenario
- 7.5.13.4. Latvia market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.14. Lithuania
- 7.5.14.1. Key country dynamics
- 7.5.14.2. Regulatory framework/Reimbursement
- 7.5.14.3. Competitive scenario
- 7.5.14.4. Lithuania market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.15. Portugal
- 7.5.15.1. Key country dynamics
- 7.5.15.2. Regulatory framework/Reimbursement
- 7.5.15.3. Competitive scenario
- 7.5.15.4. Portugal market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.16. The Netherlands
- 7.5.16.1. Key country dynamics
- 7.5.16.2. Regulatory framework/Reimbursement
- 7.5.16.3. Competitive scenario
- 7.5.16.4. The Netherlands market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.1. UK
Chapter 8. Competitive Landscape
- 8.1. Recent Developments & Impact Analysis, By Key Market Participants
- 8.2. Company/Competition Categorization
- 8.3. Vendor Landscape
- 8.3.1. List of key distributors and channel partners
- 8.3.2. Key customers
- 8.3.3. Key company market share analysis, 2023
- 8.3.4. Abbott
- 8.3.4.1. Company overview
- 8.3.4.2. Financial performance
- 8.3.4.3. Services benchmarking
- 8.3.4.4. Strategic initiatives
- 8.3.5. Nucleix
- 8.3.5.1. Company overview
- 8.3.5.2. Financial performance
- 8.3.5.3. Services benchmarking
- 8.3.5.4. Strategic initiatives
- 8.3.6. Danaher Corporation
- 8.3.6.1. Company overview
- 8.3.6.2. Financial performance
- 8.3.6.3. Services benchmarking
- 8.3.6.4. Strategic initiatives
- 8.3.7. Pacific Edge
- 8.3.7.1. Company overview
- 8.3.7.2. Financial performance
- 8.3.7.3. Services benchmarking
- 8.3.7.4. Strategic initiatives
- 8.3.8. Polymedco, LLC.
- 8.3.8.1. Company overview
- 8.3.8.2. Financial performance
- 8.3.8.3. Services benchmarking
- 8.3.8.4. Strategic initiatives
- 8.3.9. KARL STORZ
- 8.3.9.1. Company overview
- 8.3.9.2. Financial performance
- 8.3.9.3. Services benchmarking
- 8.3.9.4. Strategic initiatives
- 8.3.10. AroCell (IDL Biotech)
- 8.3.10.1. Company overview
- 8.3.10.2. Financial performance
- 8.3.10.3. Services benchmarking
- 8.3.10.4. Strategic initiatives
- 8.3.11. Micromedic Technologies
- 8.3.11.1. Company overview
- 8.3.11.2. Financial performance
- 8.3.11.3. Services benchmarking
- 8.3.11.4. Strategic initiatives
- 8.3.12. Sysmex Corporation
- 8.3.12.1. Company overview
- 8.3.12.2. Financial performance
- 8.3.12.3. Services benchmarking
- 8.3.12.4. Strategic initiatives
- 8.3.13. Vesica Health
- 8.3.13.1. Company overview
- 8.3.13.2. Financial performance
- 8.3.13.3. Services benchmarking
- 8.3.13.4. Strategic initiatives
Product Code: GVR-4-68040-467-2
List of Tables
- Table 1 List of abbreviations
- Table 2 Europe bladder cancer diagnostics market, by country, 2018 - 2030 (USD Million)
- Table 3 Europe bladder cancer diagnostics market, by technology, 2018 - 2030 (USD Million)
- Table 4 Europe bladder cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
- Table 5 Europe bladder cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
- Table 6 Germany bladder cancer diagnostics market, by technology, 2018 - 2030 (USD Million)
- Table 7 Germany bladder cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
- Table 8 Germany bladder cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
- Table 9 UK bladder cancer diagnostics market, by technology, 2018 - 2030 (USD Million)
- Table 10 UK bladder cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
- Table 11 UK bladder cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
- Table 12 France bladder cancer diagnostics market, by technology, 2018 - 2030 (USD Million)
- Table 13 France bladder cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
- Table 14 France bladder cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
- Table 15 Italy bladder cancer diagnostics market, by technology, 2018 - 2030 (USD Million)
- Table 16 Italy bladder cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
- Table 17 Italy bladder cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
- Table 18 Spain bladder cancer diagnostics market, by technology, 2018 - 2030 (USD Million)
- Table 19 Spain bladder cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
- Table 20 Spain bladder cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
- Table 21 Denmark bladder cancer diagnostics market, by technology, 2018 - 2030 (USD Million)
- Table 22 Denmark bladder cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
- Table 23 Denmark bladder cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
- Table 24 Sweden bladder cancer diagnostics market, by technology, 2018 - 2030 (USD Million)
- Table 25 Sweden bladder cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
- Table 26 Sweden bladder cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
- Table 27 Norway bladder cancer diagnostics market, by technology, 2018 - 2030 (USD Million)
- Table 28 Norway bladder cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
- Table 29 Norway bladder cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
- Table 30 Finland bladder cancer diagnostics market, by technology, 2018 - 2030 (USD Million)
- Table 31 Finland bladder cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
- Table 32 Finland bladder cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
- Table 33 Poland bladder cancer diagnostics market, by technology, 2018 - 2030 (USD Million)
- Table 34 Poland bladder cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
- Table 35 Poland bladder cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
- Table 36 Estonia bladder cancer diagnostics market, by technology, 2018 - 2030 (USD Million)
- Table 37 Estonia bladder cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
- Table 38 Estonia bladder cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
- Table 39 Latvia bladder cancer diagnostics market, by technology, 2018 - 2030 (USD Million)
- Table 40 Latvia bladder cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
- Table 41 Latvia bladder cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
- Table 42 Latvia bladder cancer diagnostics market, by technology, 2018 - 2030 (USD Million)
- Table 43 Latvia bladder cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
- Table 44 Latvia bladder cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
- Table 45 Lithuania bladder cancer diagnostics market, by technology, 2018 - 2030 (USD Million)
- Table 46 Lithuania bladder cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
- Table 47 Lithuania bladder cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
- Table 48 Portugal bladder cancer diagnostics market, by technology, 2018 - 2030 (USD Million)
- Table 49 Portugal bladder cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
- Table 50 Portugal bladder cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
- Table 51 The Netherlands bladder cancer diagnostics market, by technology, 2018 - 2030 (USD Million)
- Table 52 The Netherlands bladder cancer diagnostics market, by cancer type, 2018 - 2030 (USD Million)
- Table 53 The Netherlands bladder cancer diagnostics market, by end use, 2018 - 2030 (USD Million)
List of Figures
- Fig. 1 Market research process
- Fig. 2 Data triangulation techniques
- Fig. 3 Primary research pattern
- Fig. 4 Primary interviews in Europe
- Fig. 5 Market research approaches
- Fig. 6 Value-chain-based sizing & forecasting
- Fig. 7 QFD modeling for market share assessment
- Fig. 8 Market formulation & validation
- Fig. 9 Europe bladder cancer diagnostics market: market outlook
- Fig. 10 Europe bladder cancer diagnostics competitive insights
- Fig. 11 Parent market outlook
- Fig. 12 Related/ancillary market outlook
- Fig. 13 Penetration and growth prospect mapping
- Fig. 14 Industry value chain analysis
- Fig. 15 Europe bladder cancer diagnostics market driver impact
- Fig. 16 Europe bladder cancer diagnostics market restraint impact
- Fig. 17 Europe bladder cancer diagnostics market strategic initiatives analysis
- Fig. 18 Europe bladder cancer diagnostics market: Technology movement analysis
- Fig. 19 Europe bladder cancer diagnostics market: Technology outlook and key takeaways
- Fig. 20 Cystoscopy market estimates and forecast, 2018 - 2030 (USD Million)
- Fig. 21 CSF Cystoscopy estimates and forecast, 2018 - 2030 (USD Million)
- Fig. 22 Blood based Cystoscopy market estimates and forecast, 2018 - 2030 (USD Million)
- Fig. 23 Ultrasound estimates and forecast, 2018 - 2030 (USD Million)
- Fig. 24 Urinalysis market estimates and forecast, 2018 - 2030 (USD Million)
- Fig. 25 Others market estimates and forecasts,2018 - 2030 (USD Million)
- Fig. 26 Europe bladder cancer diagnostics Market: Cancer type movement analysis
- Fig. 27 Europe bladder cancer diagnostics market: Cancer type outlook and key takeaways
- Fig. 28 Transitional Cell Bladder Cancer market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 29 Squamous Cell Bladder Cancer market estimates and forecasts,2018 - 2030 (USD Million)
- Fig. 30 Others market estimates and forecasts,2018 - 2030 (USD Million)
- Fig. 31 Europe bladder cancer diagnostics market: End-user movement analysis
- Fig. 32 Europe bladder cancer diagnostics market: End-user outlook and key takeaways
- Fig. 33 Hospital Settings market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 34 Non Hospital Settings market estimates and forecasts,2018 - 2030 (USD Million)
- Fig. 35 Europe bladder cancer diagnostics market: Regional movement analysis
- Fig. 36 Europe bladder cancer diagnostics market: Regional outlook and key takeaways
- Fig. 37 Europe bladder cancer diagnostics market share and leading players
- Fig. 38 Europe market share and leading players
- Fig. 39 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 40 UK market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 41 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 42 France market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 43 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 44 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 45 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 46 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 47 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 48 Finland market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 49 Poland market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 50 Estonia market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 51 Lithuania market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 52 Latvia market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 53 Latvia market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 54 Portugal market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 55 The Netherlands market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 56 Market share of key market players- Europe bladder cancer diagnostics market
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.